Thrilled to share that I’ve completed my Executive MBA from @NYUStern School of Business! This incredible 2-year journey at one of the nation’s top business schools has been a transformative experience. A huge thank you to my family for their unwavering support. Grateful also to NYU Stern's faculty, administrative team, and my DC '24 EMBA classmates for their invaluable lessons and friendships. Special thanks to my mentor, @coconnormd and colleagues at Inova Schar Heart and Vascular (@ISHVnews) including @DrDamluji who convinced me to go with NYU (spot on!). Finally, I am grateful for Dr. Stephen Jones and the @InovaHealth System's Executive team for fostering a nurturing work environment that encourages growth and learning. The challenges of interventional cardiology, innovation, research, and education have always motivated me. The NYU Stern EMBA enhances my business acumen and leadership skills in ways that are hard to measure. Looking forward to the exciting opportunities that lie ahead!
Wayne Batchelor, MD
Verified account This account is verified. Learn more@_WayneBatchelor
Director, Interventional Cardiology, Inova Health System. Co-Chair STS/ACC TVT Registry. Chair, ACC Interventional Council, Adj. Prof Medicine, Duke University.
153 Following 1.2K Followers 142 Posts
Latest posts 5
Proud to Co-Chair this year's American College of Cardiology Clinical Trials Research (CTR) training program: Upping Your Game! with Pamela Douglas, Minnow Walsh, Melvin Echols, and Tracy Wang. Many thanks to our esteemed faculty and industry sponsor Medtronic. Time now to turn this work into action!
@pamelasdouglas
@ShashankSinhaMD
@MelvinEchols9
@MinnowWalsh
@MCoylewright
@EldrinL @Drroxmehran @TYWangMD
@PopmaJeffrey @ACCinTouch @Medtronic @InovaHealth @ISHVnews
@pamelasdouglas
@ShashankSinhaMD
@MelvinEchols9
@MinnowWalsh
@MCoylewright
@EldrinL @Drroxmehran @TYWangMD
@PopmaJeffrey @ACCinTouch @Medtronic @InovaHealth @ISHVnews
Happy nurses week to all the amazing individuals who have chosen this field as their calling. Thank you so much for all that you do!
So interesting to follow the phenomenal progress of transcatheter aortic valve replacement (TAVR)! Now quite routine for next day discharge (NDD). We published in JAHA that NDD appears to be safe and associated with favorable outcomes and low readmission rates within 1 year after uncomplicated Evolut TAVR: ahajournals.org/doi/10.1161/JA….
Yesterday, the FDA panel voted in favor of transcatheter tricuspid repair using Abbott's Triclip device to treat severe tricuspid valve regurgitation (TR). This, in concert with the recent approval of Edwards' Evoque transcatheter valve replacement system, advances the field forward significantly and provides much needed hope for the 1.6 million people suffering from TR. Much more work to do, but very good news for patients!